International multicentre, open-label, phase IV clinical trial to evaluate the efficacy, safety and effect on quality of life of bilastine in children with allergic rhinoconjunctivitis
Phase 4 – monitoring after market approval
Conditions:
Allergic rhinoconjunctivitis
Sponsor: Faes Farma S.A., A. Menarini Industrie Farmaceutiche Riunite S.r.l.
trial.available_in:
БГ
Overview
Trial status: Authorised
Overall AR symptoms will be evaluated through the mean change of the T5CSS score measured at baseline (V1) and after 14 days (V3) of treatment by a participant’s e-diary
Who can participate
Age group: 0-17 years
Gender: Female, Male
Target enrollment: 70 participants
БГ